1
|
Ding K, Chen F, Priedigkeit N, Brown DD, Weiss K, Watters R, Levine KM, Heim T, Li W, Hooda J, Lucas PC, Atkinson JM, Oesterreich S, Lee AV. Single cell heterogeneity and evolution of breast cancer bone metastasis and organoids reveals therapeutic targets for precision medicine. Ann Oncol 2022; 33:1085-1088. [PMID: 35764274 PMCID: PMC10007959 DOI: 10.1016/j.annonc.2022.06.005] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/23/2022] [Revised: 05/04/2022] [Accepted: 06/17/2022] [Indexed: 11/26/2022] Open
Affiliation(s)
- K Ding
- Women's Cancer Research Center, UPMC Hillman Cancer Center, Magee-Womens Research Institute, Pittsburgh, USA; Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, USA; Integrative Systems Biology Program, University of Pittsburgh, Pittsburgh, USA
| | - F Chen
- Women's Cancer Research Center, UPMC Hillman Cancer Center, Magee-Womens Research Institute, Pittsburgh, USA; Tsinghua University, Beijing, China
| | - N Priedigkeit
- Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, USA
| | - D D Brown
- Institute for Precision Medicine, University of Pittsburgh and UPMC, Pittsburgh, USA
| | - K Weiss
- Department of Orthopedic Surgery, University of Pittsburgh, Pittsburgh, USA; Musculoskeletal Oncology Laboratory, University of Pittsburgh, Pittsburgh, USA
| | - R Watters
- Women's Cancer Research Center, UPMC Hillman Cancer Center, Magee-Womens Research Institute, Pittsburgh, USA; Department of Orthopedic Surgery, University of Pittsburgh, Pittsburgh, USA; Musculoskeletal Oncology Laboratory, University of Pittsburgh, Pittsburgh, USA
| | - K M Levine
- Women's Cancer Research Center, UPMC Hillman Cancer Center, Magee-Womens Research Institute, Pittsburgh, USA
| | - T Heim
- Department of Orthopedic Surgery, University of Pittsburgh, Pittsburgh, USA; Musculoskeletal Oncology Laboratory, University of Pittsburgh, Pittsburgh, USA
| | - W Li
- Department of Orthopedic Surgery, University of Pittsburgh, Pittsburgh, USA
| | - J Hooda
- Women's Cancer Research Center, UPMC Hillman Cancer Center, Magee-Womens Research Institute, Pittsburgh, USA; Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, USA
| | - P C Lucas
- Department of Pathology, University of Pittsburgh, Pittsburgh, USA
| | - J M Atkinson
- Women's Cancer Research Center, UPMC Hillman Cancer Center, Magee-Womens Research Institute, Pittsburgh, USA; Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, USA; Institute for Precision Medicine, University of Pittsburgh and UPMC, Pittsburgh, USA
| | - S Oesterreich
- Women's Cancer Research Center, UPMC Hillman Cancer Center, Magee-Womens Research Institute, Pittsburgh, USA; Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, USA.
| | - A V Lee
- Women's Cancer Research Center, UPMC Hillman Cancer Center, Magee-Womens Research Institute, Pittsburgh, USA; Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, USA; Institute for Precision Medicine, University of Pittsburgh and UPMC, Pittsburgh, USA.
| |
Collapse
|
2
|
Tarantino P, Niman S, Erick T, Priedigkeit N, Harrison B, Giordano A, Nakhlis F, Bellon J, Parker T, Strauss S, Jin Q, King T, Overmoyer B, Curigliano G, Regan M, Tolaney S, Lynce F. 206P HER2-low inflammatory breast cancer (IBC): Clinicopathologic features and prognostic implications. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.240] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
3
|
Hartmaier RJ, Trabucco SE, Priedigkeit N, Chung JH, Parachoniak CA, Vanden Borre P, Morley S, Rosenzweig M, Gay LM, Goldberg ME, Suh J, Ali SM, Ross J, Leyland-Jones B, Young B, Williams C, Park B, Tsai M, Haley B, Peguero J, Callahan RD, Sachelarie I, Cho J, Atkinson JM, Bahreini A, Nagle AM, Puhalla SL, Watters RJ, Erdogan-Yildirim Z, Cao L, Oesterreich S, Mathew A, Lucas PC, Davidson NE, Brufsky AM, Frampton GM, Stephens PJ, Chmielecki J, Lee AV. Recurrent hyperactive ESR1 fusion proteins in endocrine therapy-resistant breast cancer. Ann Oncol 2019; 29:872-880. [PMID: 29360925 PMCID: PMC5913625 DOI: 10.1093/annonc/mdy025] [Citation(s) in RCA: 62] [Impact Index Per Article: 12.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022] Open
Abstract
Background Estrogen receptor-positive (ER-positive) metastatic breast cancer is often intractable due to endocrine therapy resistance. Although ESR1 promoter switching events have been associated with endocrine-therapy resistance, recurrent ESR1 fusion proteins have yet to be identified in advanced breast cancer. Patients and methods To identify genomic structural rearrangements (REs) including gene fusions in acquired resistance, we undertook a multimodal sequencing effort in three breast cancer patient cohorts: (i) mate-pair and/or RNAseq in 6 patient-matched primary-metastatic tumors and 51 metastases, (ii) high coverage (>500×) comprehensive genomic profiling of 287-395 cancer-related genes across 9542 solid tumors (5216 from metastatic disease), and (iii) ultra-high coverage (>5000×) genomic profiling of 62 cancer-related genes in 254 ctDNA samples. In addition to traditional gene fusion detection methods (i.e. discordant reads, split reads), ESR1 REs were detected from targeted sequencing data by applying a novel algorithm (copyshift) that identifies major copy number shifts at rearrangement hotspots. Results We identify 88 ESR1 REs across 83 unique patients with direct confirmation of 9 ESR1 fusion proteins (including 2 via immunoblot). ESR1 REs are highly enriched in ER-positive, metastatic disease and co-occur with known ESR1 missense alterations, suggestive of polyclonal resistance. Importantly, all fusions result from a breakpoint in or near ESR1 intron 6 and therefore lack an intact ligand binding domain (LBD). In vitro characterization of three fusions reveals ligand-independence and hyperactivity dependent upon the 3' partner gene. Our lower-bound estimate of ESR1 fusions is at least 1% of metastatic solid breast cancers, the prevalence in ctDNA is at least 10× enriched. We postulate this enrichment may represent secondary resistance to more aggressive endocrine therapies applied to patients with ESR1 LBD missense alterations. Conclusions Collectively, these data indicate that N-terminal ESR1 fusions involving exons 6-7 are a recurrent driver of endocrine therapy resistance and are impervious to ER-targeted therapies.
Collapse
Affiliation(s)
- R J Hartmaier
- Foundation Medicine Inc., Cambridge; Department of Pharmacology and Chemical Biolog, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, USA; Women's Cancer Research Center, Magee-Women's Research Institute, Pittsburgh, USA.
| | | | - N Priedigkeit
- Department of Pharmacology and Chemical Biolog, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, USA; Women's Cancer Research Center, Magee-Women's Research Institute, Pittsburgh, USA
| | | | | | | | - S Morley
- Foundation Medicine Inc., Cambridge
| | | | - L M Gay
- Foundation Medicine Inc., Cambridge
| | | | - J Suh
- Foundation Medicine Inc., Cambridge
| | - S M Ali
- Foundation Medicine Inc., Cambridge
| | - J Ross
- Foundation Medicine Inc., Cambridge
| | - B Leyland-Jones
- Department of Molecular and Experimental Medicine, Avera Cancer Institute, Sioux Falls, USA
| | - B Young
- Department of Molecular and Experimental Medicine, Avera Cancer Institute, Sioux Falls, USA
| | - C Williams
- Department of Molecular and Experimental Medicine, Avera Cancer Institute, Sioux Falls, USA
| | - B Park
- Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, USA
| | - M Tsai
- Minnesota Oncology, Minneapolis, USA
| | - B Haley
- UT Southwestern Medical Center, Dallas, USA
| | - J Peguero
- Oncology Consultants Research Department, Houston, USA
| | | | | | - J Cho
- New Bern Cancer Care, New Bern, USA
| | - J M Atkinson
- Women's Cancer Research Center, Magee-Women's Research Institute, Pittsburgh, USA
| | - A Bahreini
- Women's Cancer Research Center, Magee-Women's Research Institute, Pittsburgh, USA; Department of Human Genetics, University of Pittsburgh, Pittsburgh, USA; Department of Genetics and Molecular Biology, Isfahan University of Medical Sciences, Isfahan, Iran
| | - A M Nagle
- Department of Pharmacology and Chemical Biolog, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, USA; Women's Cancer Research Center, Magee-Women's Research Institute, Pittsburgh, USA
| | - S L Puhalla
- Women's Cancer Research Center, Magee-Women's Research Institute, Pittsburgh, USA; Foundation Medicine Inc., Cambridge; Department of Molecular and Experimental Medicine, Avera Cancer Institute, Sioux Falls, USA
| | - R J Watters
- Department of Pharmacology and Chemical Biolog, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, USA; Women's Cancer Research Center, Magee-Women's Research Institute, Pittsburgh, USA; Department of Orthopaedic Surgery, University of Pittsburgh, Pittsburgh, USA
| | - Z Erdogan-Yildirim
- Women's Cancer Research Center, Magee-Women's Research Institute, Pittsburgh, USA; Department of Human Genetics, University of Pittsburgh, Pittsburgh, USA
| | - L Cao
- Women's Cancer Research Center, Magee-Women's Research Institute, Pittsburgh, USA; Central South University Xiangya School of Medicine, China
| | - S Oesterreich
- Department of Pharmacology and Chemical Biolog, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, USA; Women's Cancer Research Center, Magee-Women's Research Institute, Pittsburgh, USA
| | - A Mathew
- Department of Medicine, University of Pittsburgh, Pittsburgh, USA
| | - P C Lucas
- Department of Pathology, University of Pittsburgh, Pittsburgh, USA
| | - N E Davidson
- Foundation Medicine Inc., Cambridge; Department of Molecular and Experimental Medicine, Avera Cancer Institute, Sioux Falls, USA
| | - A M Brufsky
- Foundation Medicine Inc., Cambridge; Department of Molecular and Experimental Medicine, Avera Cancer Institute, Sioux Falls, USA
| | | | | | | | - A V Lee
- Department of Pharmacology and Chemical Biolog, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, USA; Women's Cancer Research Center, Magee-Women's Research Institute, Pittsburgh, USA
| |
Collapse
|
4
|
Levine KM, Ding K, Priedigkeit N, Sikora MJ, Tasdemir N, Zhu L, Tseng GC, Jankowitz RC, Dabbs DJ, McAuliffe PF, Lee AV, Oesterreich S. Abstract P5-04-21: FGFR4 is a novel druggable target for recurrent ER-positive breast cancers. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p5-04-21] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background
Breast cancer recurrence is a major clinical problem for estrogen receptor positive (ER+) disease, even decades after initial surgery. These long-term recurrences are a challenge for invasive ductal carcinoma (IDC), and are particularly frequent for the histological subtype of invasive lobular carcinoma (ILC). To study the long-term endocrine resistance seen in ILC patients, our lab recently generated six long-term estrogen deprivation (LTED) models of ILC cells and performed RNA-Sequencing to identify differentially expressed genes that ostensibly allow these cells to grow in the absence of estrogen. We overlapped these results with a previously published microarray dataset of tamoxifen-resistant cells, and found that FGFR4 is the most consistently overexpressed gene in the setting of acquired resistance to endocrine therapy in ILC cells. From a recent publication of RNA-Seq from other LTED models, FGFR4 RNA overexpression is also seen in all five IDC cell lines.
Hypothesis
FGFR4 is an important mediator of acquired endocrine resistance in breast cancer.
Methods
To study the role of FGFR4 in vitro, we used multiple shRNAs and specific small molecule inhibition for growth assays. To study the role of FGFR4 in de novo resistance to endocrine therapy, we collected 129 well curated ER+ ILC tumor specimens and performed gene expression analysis on the pre-treatment samples using a custom NanoString panel. To study the role of FGFR4 in acquired resistance, we collected over 50 pairs of primary-metastatic ER+ tumors and performed exon capture based RNA-Sequencing.
Results
FGFR4 inhibition decreases parental and LTED cell growth in classic 2D conditions and in colony formation assays. The LTED cells, with higher FGFR4 expression, are more sensitive to its inhibition. For the parental cells, combination FGFR4 and ER-targeting drugs results in synergistic decreases in growth. In our database of primary ILC clinical samples, increased expression of FGFR4 is predictive of shorter time to distant recurrence. Among primary-recurrent tumor pairs, FGFR4 is an outlier expression gain in 20/50 (40%), spanning all recurrence sites studied (i.e. local recurrences, and metastases to the brain, bone, ovaries, and GI tract). Finally, in analyzing large cohorts of metastatic tumors, there is a significant enrichment of hotspot FGFR4 mutations in tumors originating in the breast, with >2% of metastatic ILC tumors containing such a mutation.
Conclusion/Future studies
FGFR4 may play an important role in de novo resistance to endocrine therapy in ILC and acquired resistance in both ILC and IDC. Ongoing studies include overexpression of wild-type and FGFR4 hotspot mutations in ILC and IDC cell lines to determine growth and metastatic phenotypes.
Citation Format: Levine KM, Ding K, Priedigkeit N, Sikora MJ, Tasdemir N, Zhu L, Tseng GC, Jankowitz RC, Dabbs DJ, McAuliffe PF, Lee AV, Oesterreich S. FGFR4 is a novel druggable target for recurrent ER-positive breast cancers [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P5-04-21.
Collapse
Affiliation(s)
- KM Levine
- University of Pittsburgh, Pittsburgh, PA; University of Colorado Denver, Denver, Aurora, CO
| | - K Ding
- University of Pittsburgh, Pittsburgh, PA; University of Colorado Denver, Denver, Aurora, CO
| | - N Priedigkeit
- University of Pittsburgh, Pittsburgh, PA; University of Colorado Denver, Denver, Aurora, CO
| | - MJ Sikora
- University of Pittsburgh, Pittsburgh, PA; University of Colorado Denver, Denver, Aurora, CO
| | - N Tasdemir
- University of Pittsburgh, Pittsburgh, PA; University of Colorado Denver, Denver, Aurora, CO
| | - L Zhu
- University of Pittsburgh, Pittsburgh, PA; University of Colorado Denver, Denver, Aurora, CO
| | - GC Tseng
- University of Pittsburgh, Pittsburgh, PA; University of Colorado Denver, Denver, Aurora, CO
| | - RC Jankowitz
- University of Pittsburgh, Pittsburgh, PA; University of Colorado Denver, Denver, Aurora, CO
| | - DJ Dabbs
- University of Pittsburgh, Pittsburgh, PA; University of Colorado Denver, Denver, Aurora, CO
| | - PF McAuliffe
- University of Pittsburgh, Pittsburgh, PA; University of Colorado Denver, Denver, Aurora, CO
| | - AV Lee
- University of Pittsburgh, Pittsburgh, PA; University of Colorado Denver, Denver, Aurora, CO
| | - S Oesterreich
- University of Pittsburgh, Pittsburgh, PA; University of Colorado Denver, Denver, Aurora, CO
| |
Collapse
|
5
|
Ross M, Tianzhou M, Priedigkeit N, Zhang L, Tseng G, Lee A, Edwards R, Vlad A. An in vitro evaluation of neoantigens derived from gene fusion events in ovarian cancer patients. Gynecol Oncol 2018. [DOI: 10.1016/j.ygyno.2018.04.025] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
6
|
Varešlija D, Priedigkeit N, Purcell S, O’Halloran P, Hill A, Oesterreich S, Lee A, Young L. PO-143 Recurrent transcriptional remodelling events represent clinically actionable targets in breast cancers brain metastasis. ESMO Open 2018. [DOI: 10.1136/esmoopen-2018-eacr25.666] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
|
7
|
Levine KM, Chen J, Sikora MJ, Tasdemir N, Priedigkeit N, Tseng GC, Puhalla SL, Jankowitz RC, Dabbs DJ, McAuliffe PF, Lee AV, Oesterreich S. Abstract PD4-09: Combination FGFR4 and ER-targeted therapy for invasive lobular carcinoma. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-pd4-09] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background
Invasive Lobular Carcinoma (ILC) is an understudied subtype of breast cancer that requires novel therapies in the advanced setting. Distinctive properties of ILC include growth patterns, metastatic behavior, and receptor status (almost universally estrogen receptor (ER) positive). Our lab recently generated six long-term estrogen deprivation (LTED) models of ILC cells and performed RNA-Sequencing to identify differentially expressed genes compared to their parental cells cultured with estrogen. We overlapped these results with a previously published microarray dataset and found that FGFR4 is the most consistently overexpressed gene in the setting of acquired resistance to endocrine therapy in ILC cells.
Hypothesis
FGFR4 is an important mediator of resistance to endocrine therapy in ILC.
Methods
To study the role of FGFR4 in vitro, we used multiple shRNAs and specific small molecule inhibition for growth assays of ILC cells. To study the role of FGFR4 in de novo resistance to endocrine therapy, we collected 129 well curated ER+ ILC tumor specimens and performed gene expression analysis on the pre-treatment samples using a custom NanoString panel. To study the role of FGFR4 in acquired resistance, we collected over 50 pairs of primary-metastatic ER+ tumors and performed exon capture based RNA-Sequencing.
Results
FGFR4 inhibition decreases parental and LTED ILC cell growth in classic 2D conditions, in the setting of ultra-low attachment, and in colony formation assays. The LTED cells, with higher FGFR4 expression, are more sensitive to its inhibition. For the parental cells, combination FGFR4 and ER-targeting drugs results in synergistic decreases in growth. In our database of primary ILC clinical samples, increased expression of FGFR4 is predictive of shorter time to distant recurrence. For our collection of 50 paired, primary-metastatic ER+ tissues, FGFR4 expression increases on average >2.5 fold in the metastatic setting, with large gains even in ductal carcinoma cases. Finally, in analyzing recently published cohorts of metastatic tumors, there is a significant enrichment of hotspot FGFR4 mutations in tumors originating in the breast, with >2% of metastatic ILC tumors containing such a mutation.
Conclusion
FGFR4 may play an important role in both acquired and de novo resistance to endocrine therapy in ILC.
Citation Format: Levine KM, Chen J, Sikora MJ, Tasdemir N, Priedigkeit N, Tseng GC, Puhalla SL, Jankowitz RC, Dabbs DJ, McAuliffe PF, Lee AV, Oesterreich S. Combination FGFR4 and ER-targeted therapy for invasive lobular carcinoma [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr PD4-09.
Collapse
Affiliation(s)
- KM Levine
- University of Pittsburgh, Pittsburgh, PA; University of Colorado Denver, Denver, CO
| | - J Chen
- University of Pittsburgh, Pittsburgh, PA; University of Colorado Denver, Denver, CO
| | - MJ Sikora
- University of Pittsburgh, Pittsburgh, PA; University of Colorado Denver, Denver, CO
| | - N Tasdemir
- University of Pittsburgh, Pittsburgh, PA; University of Colorado Denver, Denver, CO
| | - N Priedigkeit
- University of Pittsburgh, Pittsburgh, PA; University of Colorado Denver, Denver, CO
| | - GC Tseng
- University of Pittsburgh, Pittsburgh, PA; University of Colorado Denver, Denver, CO
| | - SL Puhalla
- University of Pittsburgh, Pittsburgh, PA; University of Colorado Denver, Denver, CO
| | - RC Jankowitz
- University of Pittsburgh, Pittsburgh, PA; University of Colorado Denver, Denver, CO
| | - DJ Dabbs
- University of Pittsburgh, Pittsburgh, PA; University of Colorado Denver, Denver, CO
| | - PF McAuliffe
- University of Pittsburgh, Pittsburgh, PA; University of Colorado Denver, Denver, CO
| | - AV Lee
- University of Pittsburgh, Pittsburgh, PA; University of Colorado Denver, Denver, CO
| | - S Oesterreich
- University of Pittsburgh, Pittsburgh, PA; University of Colorado Denver, Denver, CO
| |
Collapse
|
8
|
Priedigkeit N, Vareslija D, Basudan A, Watters RJ, Lucas PC, Davidson NE, Blohmer JU, Denkert C, Machleidt A, Heppner BI, Brufsky AM, Oesterreich S, Young L, Lee AV. Abstract GS2-03: Highly recurrent transcriptional remodeling events in advanced endocrine resistant ER-positive breast cancers. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-gs2-03] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
BACKGROUND: Although individual cancers are driven by heterogeneous processes, cancer mortality has a near universal cause—therapy resistance, recurrence and metastasis to vital organs. Characterizing more advanced tumors has borne valuable insight into cancer progression, yet studies of longitudinally collected breast cancer specimens are scarce given lengthy periods of cancer dormancy. In this study, we aimed to create the most comprehensive characterization of gene expression alterations to date between patient-matched pairs of primary and advanced ER-positive breast cancers.
MATERIALS/METHODS: Hybrid-capture RNA-sequencing was performed on 50 patient-matched pairs of primary and advanced ER-positive tumors from various recurrence sites (9 brain, 11 bone, 3 GI, 10 ovary, 17 local). Time to recurrence was up to 14.1 years with a median of 3.4 years. A shared variant analysis confirmed all paired samples were patient-matched. 1,380 cancer-related genes were analyzed for outlier expression fold-changes in matched recurrences versus primary tumors. Pair-specific, outlier fold-change thresholds were defined as Q1/Q3 +/- [1.5 X IQR]; using each pairs' fold-change values across all genes as the distribution. These discrete, longitudinal transcriptional remodeling events (LTREs) were assessed for recurrence across all sites and analyzed for enrichments within specific cohorts (Fisher's exact tests), such as locoregional vs. distant recurrences. To determine if LTREs represent acquired vulnerabilities, ex vivo and in vivo experiments targeting a recurrent, druggable LTRE gain of RET was performed.
RESULTS: The majority of advanced cancers were transcriptionally similar to patient-matched primaries with 23 of 33 distant metastases retaining PAM50 assignments of the matched primary—shifts to HER2 (n=4, 12%) or Luminal B (n=5, 15%) subtypes accounted for most metastatic discordances. Despite this intrinsic conservation, remarkably recurrent gene-level LTRE gains and losses were observed in advanced disease. Recurrent LTRE gains included NCAM1 [42%], FGFR4 [40%], IBSP [36%], ROBO2 [36%] and SPP1 [30%]. Notable LTRE losses included RELN [42%] and ESR1 [26%]. NCAM1 LTREs showed the most significant enrichments (p < 0.001) in distant disease (20 of 33, 61%) versus locoregional disease (1 of 17, 6%). A prominent LTRE enriched in brain metastasis (BrM) was RET (p-value = 0.003), expression of which showed outlier gains in 56% of ER-positive BrM. Marked anti-tumor activity was demonstrated with the RET inhibitor cabozantinib in ex vivo explant cultures of patient resected BrMs (n=3) and a BrM patient-derived xenograft.
CONCLUSIONS: Taken together, these results demonstrate profound, recurrent and metastatic site-specific LTREs in advanced breast cancers, which may be essential to our understanding of endocrine-therapy resistance and metastasis. Although current emphasis for longitudinal clinical profiling of tumors is on DNA-level alterations, these results suggest LTREs as a compelling, shared mechanism of cancer progression. Given remarkably high recurrence rates of specific LTREs across multiple cohorts, further preclinical and clinical investigations of LTREs are demanded, especially considering some (i.e. FGFR4 and RET) are readily druggable.
Citation Format: Priedigkeit N, Vareslija D, Basudan A, Watters RJ, Lucas PC, Davidson NE, Blohmer J-U, Denkert C, Machleidt A, Heppner BI, Brufsky AM, Oesterreich S, Young L, Lee AV. Highly recurrent transcriptional remodeling events in advanced endocrine resistant ER-positive breast cancers [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr GS2-03.
Collapse
Affiliation(s)
- N Priedigkeit
- University of Pittsburgh, Pittsburgh, PA; Royal College of Surgeons in Ireland, Dublin, Ireland; Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA; Charité University Hospital, Berlin, Germany
| | - D Vareslija
- University of Pittsburgh, Pittsburgh, PA; Royal College of Surgeons in Ireland, Dublin, Ireland; Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA; Charité University Hospital, Berlin, Germany
| | - A Basudan
- University of Pittsburgh, Pittsburgh, PA; Royal College of Surgeons in Ireland, Dublin, Ireland; Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA; Charité University Hospital, Berlin, Germany
| | - RJ Watters
- University of Pittsburgh, Pittsburgh, PA; Royal College of Surgeons in Ireland, Dublin, Ireland; Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA; Charité University Hospital, Berlin, Germany
| | - PC Lucas
- University of Pittsburgh, Pittsburgh, PA; Royal College of Surgeons in Ireland, Dublin, Ireland; Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA; Charité University Hospital, Berlin, Germany
| | - NE Davidson
- University of Pittsburgh, Pittsburgh, PA; Royal College of Surgeons in Ireland, Dublin, Ireland; Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA; Charité University Hospital, Berlin, Germany
| | - J-U Blohmer
- University of Pittsburgh, Pittsburgh, PA; Royal College of Surgeons in Ireland, Dublin, Ireland; Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA; Charité University Hospital, Berlin, Germany
| | - C Denkert
- University of Pittsburgh, Pittsburgh, PA; Royal College of Surgeons in Ireland, Dublin, Ireland; Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA; Charité University Hospital, Berlin, Germany
| | - A Machleidt
- University of Pittsburgh, Pittsburgh, PA; Royal College of Surgeons in Ireland, Dublin, Ireland; Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA; Charité University Hospital, Berlin, Germany
| | - BI Heppner
- University of Pittsburgh, Pittsburgh, PA; Royal College of Surgeons in Ireland, Dublin, Ireland; Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA; Charité University Hospital, Berlin, Germany
| | - AM Brufsky
- University of Pittsburgh, Pittsburgh, PA; Royal College of Surgeons in Ireland, Dublin, Ireland; Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA; Charité University Hospital, Berlin, Germany
| | - S Oesterreich
- University of Pittsburgh, Pittsburgh, PA; Royal College of Surgeons in Ireland, Dublin, Ireland; Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA; Charité University Hospital, Berlin, Germany
| | - L Young
- University of Pittsburgh, Pittsburgh, PA; Royal College of Surgeons in Ireland, Dublin, Ireland; Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA; Charité University Hospital, Berlin, Germany
| | - AV Lee
- University of Pittsburgh, Pittsburgh, PA; Royal College of Surgeons in Ireland, Dublin, Ireland; Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA; Charité University Hospital, Berlin, Germany
| |
Collapse
|
9
|
Priedigkeit N, Hartmaier RJ, Chen Y, Vareslija D, Basudan A, Thomas R, Leone JP, Lucas PC, Bhargava R, Hamilton RL, Chmielecki J, Davidson NE, Oesterreich S, Brufsky AM, Young L, Lee AV. Abstract PD1-05: Breast cancer brain metastases show limited intrinsic subtype switching, yet exhibit acquired ERBB2 amplifications and activating mutations. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-pd1-05] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
BACKGROUND: Metastasis is the major cause of mortality in breast cancer (BrCa) patients. Our understanding of brain metastasis (BrM) is limited, reflected by a lack of effective treatments. We aimed to (1) determine BrCa gene signature differences between primary tumors and matched BrM and (2) uncover BrM-specific alterations that may be clinically actionable.
MATERIALS and METHODS: NanoString expression profiling of 127 genes from 5 major prognostic tests (MammaPrint, EndoPredict, PAM50, OncotypeDX, MGI) was performed on 20 patient-matched primary (10 ER-neg, 10 ER-pos) and metastatic brain tumors. Subtype classification was performed using genefu. Protein changes in ER and HER2 (ERBB2) were confirmed by IHC. BrM-specific ERBB2 gains were corroborated in a publicly available dataset of 18 additional patient-matched cases (dbGAP phs000730.v1.p1). To test whether ERBB2 amplification and base pair mutation is metastasis-site specific, we further analyzed an expanded cohort of 7,884 breast tumors enriched for metastatic samples (52%) including liver (16.7%), lung (4.3%), bone (3.6%), and brain (2.0%) using comprehensive hybrid-capture sequencing of ERBB2.
RESULTS: 17/20 BrM retained the PAM50 subtype of the primary BrCa. Despite this concordance, 17/20 BrM harbored expression changes (< or > 2-fold) in clinically actionable genes including gains of FGFR4 (30%), FLT1 (20%), AURKA (10%) and loss of ESR1 expression (45%). The most recurrently upregulated gene was ERBB2, showing a >2-fold expression increase in 35% of BrM. 3 of 13 (23.3%) cases originally HER2-negative, and thus HER2-therapy naive, in the primary BrCa were IHC-positive (3+) in the paired BrM with an observed metastasis-specific amplification of the ERBB2 locus. In an independent dataset, 2 of 9 (22.2%) HER2-negative BrCa switched to HER2-positive with one BrM acquiring ERBB2 amplification and the other showing metastastic enrichment of the activating V777L ERBB2 mutation. Analysis of a large cohort of breast tumors (n=7,884) showed that across all organs ERBB2 amplification and/or base pair mutation was similar (p=0.18) between primary (13%) and metastatic disease (12%), however, a strong and significant enrichment was seen for BrM (primary 13% vs BrM 24%, p<0.0005).
CONCLUSIONS: Taken together, these results demonstrate that the majority (85%) of patient-matched BrM retain the intrinsic subtype of the primary cancer. However, despite this transcriptional similarity, alterations in clinically actionable genes are common, with BrM acquiring ERBB2 amplifications and/or base pair mutations at a frequency of ∼20%, even in HER2-therapy naive tumors. In a large cohort of primary and metastatic breast cancers, there is also a unique enrichment for ERBB2 alterations in BrM. This study provides a strong rationale to molecularly profile metastatic lesions to both better understand biological mechanisms of metastases and to perhaps refine therapeutic decision-making in advanced cancers.
Citation Format: Priedigkeit N, Hartmaier RJ, Chen Y, Vareslija D, Basudan A, Thomas R, Leone JP, Lucas PC, Bhargava R, Hamilton RL, Chmielecki J, Davidson NE, Oesterreich S, Brufsky AM, Young L, Lee AV. Breast cancer brain metastases show limited intrinsic subtype switching, yet exhibit acquired ERBB2 amplifications and activating mutations [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr PD1-05.
Collapse
Affiliation(s)
- N Priedigkeit
- University of Pittsburgh, Pittsburgh, PA; Foundation Medicine Inc., Cambridge, MA; Royal College of Surgeons, Dublin, Leinster, Ireland; University of Iowa, Iowa City, IA
| | - RJ Hartmaier
- University of Pittsburgh, Pittsburgh, PA; Foundation Medicine Inc., Cambridge, MA; Royal College of Surgeons, Dublin, Leinster, Ireland; University of Iowa, Iowa City, IA
| | - Y Chen
- University of Pittsburgh, Pittsburgh, PA; Foundation Medicine Inc., Cambridge, MA; Royal College of Surgeons, Dublin, Leinster, Ireland; University of Iowa, Iowa City, IA
| | - D Vareslija
- University of Pittsburgh, Pittsburgh, PA; Foundation Medicine Inc., Cambridge, MA; Royal College of Surgeons, Dublin, Leinster, Ireland; University of Iowa, Iowa City, IA
| | - A Basudan
- University of Pittsburgh, Pittsburgh, PA; Foundation Medicine Inc., Cambridge, MA; Royal College of Surgeons, Dublin, Leinster, Ireland; University of Iowa, Iowa City, IA
| | - R Thomas
- University of Pittsburgh, Pittsburgh, PA; Foundation Medicine Inc., Cambridge, MA; Royal College of Surgeons, Dublin, Leinster, Ireland; University of Iowa, Iowa City, IA
| | - JP Leone
- University of Pittsburgh, Pittsburgh, PA; Foundation Medicine Inc., Cambridge, MA; Royal College of Surgeons, Dublin, Leinster, Ireland; University of Iowa, Iowa City, IA
| | - PC Lucas
- University of Pittsburgh, Pittsburgh, PA; Foundation Medicine Inc., Cambridge, MA; Royal College of Surgeons, Dublin, Leinster, Ireland; University of Iowa, Iowa City, IA
| | - R Bhargava
- University of Pittsburgh, Pittsburgh, PA; Foundation Medicine Inc., Cambridge, MA; Royal College of Surgeons, Dublin, Leinster, Ireland; University of Iowa, Iowa City, IA
| | - RL Hamilton
- University of Pittsburgh, Pittsburgh, PA; Foundation Medicine Inc., Cambridge, MA; Royal College of Surgeons, Dublin, Leinster, Ireland; University of Iowa, Iowa City, IA
| | - J Chmielecki
- University of Pittsburgh, Pittsburgh, PA; Foundation Medicine Inc., Cambridge, MA; Royal College of Surgeons, Dublin, Leinster, Ireland; University of Iowa, Iowa City, IA
| | - NE Davidson
- University of Pittsburgh, Pittsburgh, PA; Foundation Medicine Inc., Cambridge, MA; Royal College of Surgeons, Dublin, Leinster, Ireland; University of Iowa, Iowa City, IA
| | - S Oesterreich
- University of Pittsburgh, Pittsburgh, PA; Foundation Medicine Inc., Cambridge, MA; Royal College of Surgeons, Dublin, Leinster, Ireland; University of Iowa, Iowa City, IA
| | - AM Brufsky
- University of Pittsburgh, Pittsburgh, PA; Foundation Medicine Inc., Cambridge, MA; Royal College of Surgeons, Dublin, Leinster, Ireland; University of Iowa, Iowa City, IA
| | - L Young
- University of Pittsburgh, Pittsburgh, PA; Foundation Medicine Inc., Cambridge, MA; Royal College of Surgeons, Dublin, Leinster, Ireland; University of Iowa, Iowa City, IA
| | - AV Lee
- University of Pittsburgh, Pittsburgh, PA; Foundation Medicine Inc., Cambridge, MA; Royal College of Surgeons, Dublin, Leinster, Ireland; University of Iowa, Iowa City, IA
| |
Collapse
|
10
|
Chen Y, Kalir E, Priedigkeit N, Kalir T, Liu Y, Hu W, Sood A, Radu A, Dottino P, Martignetti J. Follicle-stimulating hormone receptor expression analysis in serous ovarian tumors suggests a disease continuum from low malignant potential to low-grade carcinoma. Gynecol Oncol 2012. [DOI: 10.1016/j.ygyno.2011.12.348] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|